What Pasireotide is
Pasireotide is a somatostatin analog used in approved endocrine contexts with receptor-binding differences from older analogs.
Pasireotide is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it shows how even within peptide analog families, receptor profile still matters clinically.
The useful starting point is to separate the molecule itself from the internet story around it. It shows how even within peptide analog families, receptor profile still matters clinically.
Why people keep looking it up
It shows how even within peptide analog families, receptor profile still matters clinically.
Pasireotide is a somatostatin analog used in approved endocrine contexts with receptor-binding differences from older analogs.
Pasireotide tends to stay in the conversation because it touches a familiar public theme: somatostatin analog, hormone suppression, and pituitary disease. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved somatostatin analog with direct human evidence.
Human trials and labeling support specific approved uses.
Mechanistic support follows somatostatin-receptor pharmacology.
Why this page carries the current tier: Approved somatostatin analog with direct human evidence.
The current seed trail for Pasireotide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a serious endocrine medicine, not a casual metabolism or performance peptide.
FDA-approved pasireotide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Pasireotide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Pasireotide is CID 9941444. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 9941444
- Formula
- C58H66N10O9
- Molecular weight
- 1047.2
- InChIKey
- VMZMNAABQBOLAK-DBILLSOUSA-N
Matched synonyms include Pasireotide, 396091-73-9, SOM-230, SOM230, SOM 230, pasireotida, pasireotidum, CHEBI:72312.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Pasireotide returns 86 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Pasireotide returns 839 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Signifor
- Generic names
- PASIREOTIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA200677
Indications and usage. 1 INDICATIONS AND USAGE SIGNIFOR is a somatostatin analog indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative ( 1 ) 1.1 Cushing's Disease SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Hypocortisolism : Decreases in circulating levels of cortisol may occur resulting in biochemical and/or clinical hypocortisolism. SIGNIFOR dose reduction or interruption and/or adding a low-dose short-term glucocorticoid may be necessary ( 5.1 ) Hyperglycemia and Diabetes (occurs with initiation) : Intensive glucose monitoring is recommended and may require initiation or adjustment of anti...
Contraindications. 4 CONTRAINDICATIONS None. None ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.